Stacy Murphy
Psychiatric/Mental Health · Ottumwa, IANPI 1104435791
Payments from drug & device makers
Across 250 payments — averaging $13.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$326
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$272
- Otsuka America Pharmaceutical, Inc.$260
- Teva Pharmaceuticals USA, Inc.$256
- Johnson & Johnson$208
- plus $1K from 9 others
What the payments were for
- Food & beverage$3,44899%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 108 | $1,100 |
| Alkermes, Inc. | 18 | $326 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $272 |
| Otsuka America Pharmaceutical, Inc. | 16 | $260 |
| Teva Pharmaceuticals USA, Inc. | 16 | $256 |
| Johnson & Johnson | 13 | $208 |
| Vanda Pharmaceuticals Inc. | 10 | $207 |
| Lundbeck LLC | 13 | $203 |
| Ironshore Pharmaceuticals Inc. | 9 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $134 |
| Neurocrine Biosciences, Inc. | 7 | $117 |
| Sunovion Pharmaceuticals Inc. | 7 | $103 |
| Supernus Pharmaceuticals, Inc. | 5 | $77 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Corium, LLC | 3 | $36 |
How this compares
$3,495 in reported general payments places this provider in the 80th percentile of 443 psychiatric/mental health providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 38 | $437,075 |
| Austedo XrDeutetrabenazine | 13 | $173,625 |
| VraylarCariprazine Hcl | 84 | $119,482 |
| AristadaAripiprazole Lauroxil | 23 | $66,274 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $23,390 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,622 |
| Clozapine | 56 | $4,366 |
| Quetiapine Fumarate | 121 | $4,007 |
| Olanzapine | 240 | $3,995 |
| Doxepin Hcl | 12 | $3,593 |
| Lisdexamfetamine Dimesylate | 17 | $3,563 |
| Vilazodone Hcl | 37 | $3,304 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 64 | $3,226 |
| Hydroxyzine Hcl | 113 | $2,856 |
| Buspirone Hcl | 190 | $2,595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $256 | $610,70051 claims |
| AbbVieVraylar | $1,100 | $119,48284 claims |
| Alkermes, Inc.Aristada, Lybalvi | $326 | $89,66436 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $134 | $5,62212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 443 psychiatric/mental health providers in Iowa.
Other psychiatric/mental health in Ottumwa
- Tarrah HollidayAtlantic$421K
- Kelsie SwisherParkersburg$235K
- Jennifer BradleyCedar Rapids$66K
- Kama AusbornWaterloo$64K
- Quentin ChambersDes Moines$40K
- Tenaea JeppesonFort Dodge$38K
- Jennifer WittmanCoralville$25K
- Amy MorinCedar Rapids$24K
- Jenna BerendzenCedar Falls$22K
- Daniel WesemannDavenport$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.